


Application No. PCT/US03/17347  
Amendment dated December 2, 2004  
Preliminary Amendment

**REMARKS**

Applicants have attached an abstract on a separate sheet of paper as required by U.S. practice. Applicants have amended the specification for purposes of adding the priority information. Claims 23, 24, and 27 - 31 have been cancelled. Claims 4, 7, 8, 9, 12, 13, 14, 15, 18 - 22 and 25 have been amended to remove multiple dependencies. Claims 1 - 22 and 25 - 26 remain in the application. No new matter has been added. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date: December 2, 2004



Karen L. Prus  
Attorney of Record, Reg. No 39,337

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: 919-483-2192  
Fax: 919-483-7988